Topics:
Radiation Oncology • Palliation
Is there a role for Radium-223 in patients that have a non-prostate malignancy who otherwise would be a reasonable candidate?
Answer from: Radiation Oncologist at Community Practice
At present the only approved indication for Radium-223 is in castrate resistant, symptomatic bone mets from prostate cancer. We do have open study evaluating efficacy in hormone positive breast cancer with metastases to bone.
Sign in or Register to read more